Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists

Mar 27, 2026Diabetes, obesity & metabolism

Managing weight gain and heart health risks after stopping GLP-1 diabetes drugs

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Discontinuation of GLP-1 receptor agonists is associated with 60%-90% weight regain within one year.

Substantial weight regain occurs following discontinuation, indicating poor long-term maintenance of weight loss.
Cardiometabolic benefits reverse alongside weight regain, with glycaemic, blood pressure, and lipid levels returning to baseline within about 12 months.
HbA1c levels normalize within 12-18 months after stopping treatment.
Early discontinuation, particularly within the first year, increases the risk of coronary artery disease and heart failure.
Biological adaptations, such as the reactivation of appetite-stimulating pathways, may contribute to weight recurrence.

AI simplified

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin therapies produce substantial weight loss and cardiometabolic improvement, yet treatment discontinuation is common and associated with adverse metabolic consequences.

AIMS: This review aims to synthesize current mechanistic and clinical evidence on metabolic trajectories following GLP-1RA discontinuation, identify predictors of relapse, and propose a multidisciplinary framework for post-treatment management.

MATERIALS AND METHODS: We conducted a narrative review of evidence from randomized withdrawal trials (including STEP-1 extension, STEP-4, and SURMOUNT-4), systematic reviews, meta-analyses, and large real-world observational cohorts encompassing over 289,000 patients.

RESULTS: Discontinuation is associated with substantial weight regain (60%-90% within one year) and parallel reversal of cardiometabolic benefits. Modelling studies suggest that glycaemic, blood pressure, and lipid parameters return to baseline within approximately 12 months, while HbA1c normalizes within 12-18 months. Early discontinuation (< 1 year) is associated with increased risks of coronary artery disease and heart failure compared with continued therapy.

DISCUSSION: Weight recurrence reflects biological adaptations to weight loss, including reactivation of orexigenic pathways and adaptive thermogenesis. In the absence of validated tapering strategies, structured multidisciplinary transition approaches combining pharmacological, behavioral, and psychological interventions may mitigate post-discontinuation relapse.

CONCLUSION: GLP-1RA discontinuation should be considered a high-risk clinical transition rather than a treatment endpoint. Structured follow-up and multidisciplinary management are essential to preserve long-term cardiometabolic benefits.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP ‐1 Receptor Agonists

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief